ARTICLE
Auteur(s) : Isabel FERNÁNDEZ-ÁNGEL1, Alberto
RODRÍ2, José ANEIROS CACHAZA3, Mónica MUÑOZ
MEDINA1, Salvio SERRANO ORTEGA1
1Department of Dermatology, San Cecilio University
Hospital, C/ Torre del Capitán no 12, Edif. Gala
Portal 1 2°A, 18008 Granada, Spain.
2Department of Oral Medicine, School of Dentistry,
University of Granada, Spain.
3Department of Pathology, San Cecilio University Hospital,
Granada, Spain.
Reprints: I. Fernández-Ángel Fax: (+34)958 243 795
E-mail: alberodrugr.es
Article accepted on 11/03/2003
Lip cancer is a form of oral cancer at the junction between the
oral cavity and the skin [1] that appears predominantly in white
males [2]. The lower incidence among females may be due to their
frequent use of lip solar protection and lesser occupational
exposure [3]. The maximum incidence of lip cancer is during the
sixth and seventh decades of life, and the lower lip is more
frequently affected than the upper [2, 4, 5]. More than 90% of
malignant tumours of the lip are squamous cell carcinomas
[6].
The highest incidence of lip cancer world-wide is recorded in the
South of Australia, with
13.49 cases/100,000 inhabitants/year in males and
3.21 cases/100,000 inhabitants/year in females. In
Europe, Granada (Spain) presents the highest male incidence
(12.70 cases/100,000 inhabitants/year and Graubunden
(Switzerland) the highest female incidence
(0.83 cases/100,000 inhabitants/year) [7].
The elevated incidence in our area of lip cancer, the non-melanoma
skin cancer that most commonly presents lymph node involvement,
prompted us to study prognostic factors that could indicate the
need for treatment of lymph node metastases.
Material and methods
A retrospective study was conducted of the 308 patients
diagnosed with and treated for squamous cell carcinoma of the lower
lip at our Surgical/Medical Clinic of Dermatology during a 10-year
period from 1985 to 1995. Every patient in the study had a minimum
follow-up of 5 years. Out of the 308 patients,
57 were excluded from the study because of missing follow-up
data.
A data collection protocol was applied to all patients. The
clinical parameters considered (Table I)
were: age (in years); gender; localization of tumour on lower lip
(right, left, middle, commissure, various other localizations);
size (maximum and minimum diameters in centimetres); presence or
absence of ulceration; and presence of lymph node metastasis,
considering both the number of lymph nodes involved (in three
categories: 1-3 nodes;
4-6 nodes; > 6 nodes) and their localization
(chains: submaxillary, submandibular, jugular, submaxillary +
submandibular, submaxillary + jugular, submandibular +
jugular).
Table I. Description of clinical
variables of patients in the study (n = 251).
|
Variable |
n (%) |
|
Gender |
|
| Male |
227 (90.44%) |
|
Female |
24
(9.56%) |
|
Localization of lesions |
|
| Lower
right lip |
108 (43.03%) |
| Lower left
lip |
71
(28.29%) |
| Lower
middle lip |
47
(18.72%) |
| Lip
commissure |
14
(5.58%) |
| Various
lower lip localizations |
11
(4.38%) |
|
Presence of ulceration |
|
|
Ulcerated |
182 (72.51%) |
| Non-
ulcerated |
69
(27.49%) |
| Lymph
node metastasis |
|
| No |
235 (93.62%) |
| Yes |
16
(6.38%) |
| Number
of nodes involved |
|
|
1-3 nodes |
7
(2.78%) |
|
4-6 nodes |
7
(2.78%) |
|
> 6 nodes |
2
(0.79%) |
| Lymph
node chain involved |
|
|
Submaxillary |
3
(1.19%) |
|
Submandibular |
2
(0.79%) |
|
Jugular |
0
(0.00%) |
|
Submaxillary + Submandibular |
2
(0.79%) |
|
Submaxillary + Jugular |
5
(1.99%) |
|
Submandibular + Jugular |
4
(1.59%) |
Statistical analysis
The data were expressed as means ± standard deviation
and percentages. The chi-square test was used to compare
qualitative variables and the Student’s t test and Mann-Whitney
test to compare quantitative variables. Bivariate and multivariate
analyses were carried out, determining the cross-product Odds Ratio
with a 95% confidence interval (CI). The statistical software
package SPSS 9.0 for Windows was used for the data
analysis.
Results
All patients in our study (n = 251) were or had been
smokers and lived in rural areas; most of them had outdoor
occupations (farmers, labourers or fishermen); 227 patients
(90.44%) were males, with a mean age of
63.27 ± 12.62 years. Almost half the tumours
(43.03%) were localized on the right lower lip, 28.29% on the left
and 18.72% in the middle area; the carcinoma was localized in a
commissure in only 14 patients (5.58%), while 11 (4.38%)
showed involvement of more than one of these localizations.
The mean maximum diameter of the tumours was
1.41 ± 1.17 cm (range, 0.2 - 10 cm) and
the mean minimum diameter was
1.03 ± 0.64 centimetres (range, 0.2 -
4 cm); 72.51% of the tumours were ulcerated.
Lymph node metastases appeared in 16 (6.38%) of the
251 tumours studied. Table I lists the
number of lymph nodes with metastases and the cervical lymph node
chains involved.
In the bivariate analysis, the females with lip cancer
(73.75 ± 12.28 years) were found
to be significantly (p < 0.001) older than the males
(62.16 ± 12.16 years). There was a statistically significant
relationship between the presence of ulceration and lymph node
involvement (p < 0.05). All of the metastatic tumours
(n = 16) were ulcerated (Table
II). There was also a statistically significant
relationship between the presence of lymph node metastases and both
the maximum (p < 0.05) and minimum
(p < 0.05) diameters. Metastatic tumours presented a
mean maximum diameter of 2.45 ± 1.93 cm and minimum
diameter of 1.40 ± 0.73 cm, whereas non-metastatic
tumours had smaller maximum and minimum diameters of
1.33 ± 1.06 cm and 1.01 ± 0.63 cm,
respectively.
Table II. Distribution of
tumours according to clinical appearance and presence of lymph node
metastasis.
|
Lymph node metastasis |
|
|
| Presence
of ulceration |
Yes |
No |
Total |
P |
|
Ulcerated |
16 |
166 |
182 |
< 0.05 |
|
Non-ulcerated |
0 |
69 |
69 |
|
|
Total |
16 |
235 |
251 |
|
P: Probality
When the presence of lymph node metastases was considered as
reference variable in the bivariate analysis (Table III), the age at diagnosis was not a
risk factor that influenced the appearance of lymph node metastases
(OR 1.013; 95% CI = 0.97 – 1.06). However, when the
presence of lymph node metastases was compared with the different
tumour localizations, it was observed that 31.25% of the metastatic
tumours were localized in the commissures and the relationship
between tumour localization and presence of lymph node metastases
was very significant (p < 0.001) (Table IV). As a result, we divided the tumours
between those of commissural localization and those at other
localizations in the lower lip (Table
V), and found that 35.7% of the tumours in the commissure
were metastatic, compared with only 4.6% of the tumours at other
localizations (p < 0.001). Commissural localization
is, therefore, a major risk factor that increases more than 11-fold
the risk of lymph node metastases (OR 11.06; 95%
CI = 3.17 – 38.59).
Table III. Bivariate model.
Adjusted odds ratio with 95% confidence interval for presence of
lymph node metastasis according to age, localization and tumour
area.
| VARIABLE |
OR |
95%
CI |
| Age |
1.013 |
(0.97 – 1.06) |
|
Localization |
|
|
| Non-
commissural |
1 |
1 |
|
(Ref.) |
|
|
|
Commissural |
11.060 |
(3.17 –38.59) |
| Tumour
area |
1.170 |
(1.03 – 1.32) |
OR: Odds Ratio; CI: confidence interval Ref:
Reference category
Table IV. Distribution of
tumours by tumour localization and presence of lymph node
metastasis.
|
Lymph node metastasis
|
|
|
| Tumour
localization |
Yes |
No |
Total |
P |
| Lower right
lip |
3 |
105 |
108 |
< 0.001 |
| Lower left
lip |
4 |
67 |
71 |
|
| Lower middle
lip |
1 |
46 |
47 |
|
| Lip
commissure |
5 |
9 |
14 |
|
| Various lower lip
localizations |
3 |
8 |
11 |
|
| Total |
16 |
235 |
251 |
|
P: Probability.
Table V. Distribution of
tumours by commissural/other localization and presence of lymph
node metastasis.
|
Lymph node metastasis |
|
|
|
Localization |
Yes |
No |
% Metastatic tumours |
| Commissure* |
5 |
9 |
35.7% |
p < 0.001 |
| Other
localizations |
11 |
226 |
4.6% |
|
| Total |
16 |
235 |
|
|
*OR: 11.06 (3.17-38.59)
We also observed that tumours with lymph node metastases had a
greater mean tumour area (3.43 cm2) with respect to
non-metastatic tumours (1.34 cm2). The increase in
tumour area was a risk factor for developing lymph node metastases
(OR 1.17; 95% CI = 1.03 – 1.32).
Table VI displays the multivariate model,
which included the patient age and the tumour area and
localization. As in the bivariate model, age was not a risk factor
for the appearance of lymph node metastases (OR 1.01; 95%
CI = 0.95 – 1.06), while tumour area was no longer a
significant risk factor (OR 1.08; 95% CI = 0.97 –
1.24). As found in the bivariate model, localisation in commissure
was a major risk factor that increased 8-fold the risk of
developing lymph node metastases (OR 8.02; 95%
CI = 2.05 – 31.37).
Table VI. Multivariate model.
Adjusted odds ratio with 95% confidence interval for presence of
lymph node metastasis according to age, localization and tumour
area.
| VARIABLE |
OR |
95% CI |
| Age |
1.01 |
(0.95
–1.06) |
| Localization |
|
|
|
Non-commissural (Ref.) |
1 |
1 |
| Commissural |
8.02 |
(2.05 –
31.37) |
| Tumour area |
1.08 |
(0.97
– 1.24) |
OR: Odds Ratio; CI: confidence interval; Ref:
Reference category
Discussion
Cancer of the lip is the most frequent tumour of the orofacial
area [7] and generally appears in adulthood, especially between the
ages of 60 and 70 years [8]. The results of the present
study are consistent with these data and showed a mean age of
63.27 years.
Most authors agree that lip cancer presents a clear predilection
for the male gender. Worldwide, the male: female ratio ranges from
5.7: 1 [9] to 11: 1 [10]. We found a marked predominance
of males (90.44%) with lip cancer with respect to females (9.56%),
a ratio of 9.4: 1, very similar to the 9.2: 1 ratio reported
by Antoniades et al. [11].
In our series, the mean age of lip cancer detection in the females
(73.75 years) was significantly (p < 0.001)
higher than that in the males (62.16 years). On average, this
tumour appeared around ten years earlier in males. De Visscher
et al. [9] found a smaller five-year difference in the age
of lip cancer appearance in Holland (68 years in males vs.
73 years in females). This variability may be due to
geographical, climatic, social and cultural differences.
There are few studies on the localization of tumours in different
areas of the lower lip (left, right, middle or commissure). The
only study we found, by Bouquot et al. [12], reported that
1-2% of lip cancers involved the commissures, somewhat lower than
the 5.58% of tumours at this localization in our series.
A finding of interest, which we have been unable to compare with
other published results, was that 35.71% of the tumours localized
in the commissure presented lymph node metastases and, therefore, a
worse prognosis. The percentage of metastatic tumours at other
localizations in the lower lip was much lower, ranging from 2.2% of
tumours in the middle to 5.63% of tumours on the left side. We
found a highly significant association between tumour localisation
and presence of lymph node metastases (p < 0.001),
indicating a worse prognosis for commissural tumours.
The majority of tumours in our study (mean maximum diameter:
1.41 cm) were T1 tumours (of size below 2 cm), consistent
with findings by numerous other studies that most of these lesions
are classified in the T1 stage [11, 13-15]. The vast majority
(93.62%) of our series of tumours did not have lymph node
metastases (N0), whereas the remaining 6.38% presented metastasis
in one of the cervical lymph node chains adjacent to the tumour.
This percentage of lip cancers with metastasis is similar to other
reports, which range from 7.59% [11] to 14% [14]. We have found no
published study that individually analysed the cervical lymph nodes
involved.
One hundred and eighty-two (72.51%) of our series of lip cancers
were ulcerated, in line with the finding by most studies of a
higher frequency of ulcerated forms [16-18]. An interesting
hypothesis, which has been raised elsewhere [18] but has yet to be
tested, is that a persistent ulcerated lesion on the lip causes
patients greater concern and produces an earlier visit to a
specialist. More than 8% of the ulcerated tumours in our series
presented lymph node metastases, whereas none of the non-ulcerated
tumours were metastatic, a statistically significant difference
(p < 0.05).
In our series, the metastatic tumours had a significantly
(p < 0.05) greater mean size (2.45 ±
1.93 cm) than that of the non-metastatic tumours
(1.40 ± 1.07 cm.).
Lymph node involvement is widely considered [19, 20] to be one
of the factors with greatest influence on the tumour prognosis.
Five-year survival rates of 65% have been reported in tumours with
no lymph node involvement (N0), compared with 20% in those with
some lymph node involvement and 13% in tumours with two or more
lymph nodes involved [21]. These observations underline the
importance of the early diagnosis of any cancer and especially of
lip cancer, which has an excellent 80% five-year survival rate when
detected early.
Our bivariate and multivariate analyses, designed to establish
the influence of different parameters on the risk of developing
lymph node metastases in lip cancer, revealed that age and tumour
area are not risk factors for developing lymph node metastases.
However, localization at the commissure emerged as a very important
risk factor that increased this risk 11-fold in the bivariate model
and 8-fold in the multivariate model. We have found no other study
that analyzed the influence of tumour localisation on the risk of
cervical lymph node metastases.
In our view, wider research is warranted to consider other risk
factors that may be implicated in lip cancer besides the
aetiological factors widely studied to date.
Our results indicate that special attention should be paid to
tumours on the lip that are of large size, ulcerated or localised
in the commissure, which carry a worse prognosis.
References
1. World Health Organisation. International
statistical classification of diseases, injuries and causes of
death, 9th revision. Geneva: World Health Organisation,
1975.
2. Krolls SO, Hoffman S. Squamous cell carcinoma of
the oral soft tissues: a statistical analysis of 14.253 cases
by age, sex and race of patients. J Am Dent Assoc 1976; 92:
571-574.
3. Pogoda JM, Preston-Martin S. Solar radiation, lip
protection, and lip cancer in Los Angeles County women. Cancer
Causes Control 1996; 7: 458-63.
4. Fahmy MS, Sadeghi A, Behmard S. Epidemiologic
study of oral cancer in Fars Province, Iran. Community Dent Oral
Epidemiol 1983; 11: 50-58.
5. Faye-Lund H, Abdelnoor M. Prognostic factors of
survival in a cohort of head and neck cancer patients in Oslo.
Eur J Cancer B Oral Oncol 1996; 32B: 83-90.
6. De Visscher JG, van der Waal I. Etiology of
cancer of the lip. A review. Int J Oral Maxillofac Surg
1998; 27: 199-203.
7. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young
J. Cancer incidence in five continents. Vol VII.
International Agency for Research on Cancer. Lyon: IARC Scientific
Publication No 143, 1997.
8. Silverman S. Epidemiology. In: Oral
Cancer. 3rd ed. Atlanta: The American Cancer
Society, 1990: 1-3.
9. De Visscher JG, Schaapveld M, Otter R, Visser O,
van der Waal I. Epidemiology of cancer of the lip in The
Netherlands. Oral Oncol 1998; 34: 421-26.
10. Esclamado RM, Krause CJ. Lip Cancer. In: Bailey
BJ, eds. Head and Neck Surgery Otolaryngology. Philadelphia:
JB Lippincott, 1993: 1148-1159. 11
11. Antoniades DZ, Styanidis K, Papanayotou P,
Trigonidis G. Squamous cell carcinoma of the lips in a northern
Greek population. Evaluation of prognostic factors on 5-year
survival rate-I. Eur J Cancer B Oral Oncol 1995; 31B:
333-9.
12. Bouquot JE, Gundlach KKH. Odd lips: the
prevalence of common lip lesions in 23,616 white Americans
over 35 years of age. Quintessence Int 1987; 18:
277-284.
13. Veness MJ, Ong C, Cakir B, Morgan G. Squamous
cell carcinoma of the lip. Patterns of relapse and outcome:
Reporting the Westmead Hospital experience, 1980-1997. Australas
Radiol 2001; 45: 195-9.
14. Tombolini V, Bonanni A, Valeriani M, Zurlo A,
Vitturini A. Brachytherapy for squamous cell carcinoma of the lip.
The experience of the Institute of Radiology of the University of
Rome “La Sapienza”. Tumori 1998; 84: 478-82.
15. De Visscher JG, Grond AJ, Botke G, van der Waal
I. Results of radiotherapy for squamous cell carcinoma of the
vermilion border of the lower lip. A retrospective analysis of
108 patients. Radiother Oncol 1996; 39: 9-14.
16. Erisen L, Basut O, Tezel I, Onart S, Arat M,
Hizalan I, Coskun H. Regional epidemiological features of lip, oral
cavity, and oropharyngeal cancer. J Environ Pathol Toxicol
Oncol 1996; 15: 225-9.
17. Daniele E, Rodolico V, Leonardi V, Tralongo V.
Prognosis in lower lip squamous cell carcinoma: assessment of tumor
factors. Pathol Res Pract 1998; 194: 319-24.
18. Kerdpon D, Sriplung H. Factors related to
advanced stage oral squamous cell carcinoma in southern Thailand.
Oral Oncol 2001; 37: 216-21.
19. Di Stefani A, Magnano M, Bussi M, Cravero L,
Lerda W, Usai A, Cavalot A, Ragona R, Gabriele P, Valente G,
Cortesina G. Identification of clinical, biological and prognostic
factors in recurring squamous cell carcinoma of the head and neck.
Acta Otorhinolaryngol Ital 1997; 17: 219-24.
20. Leemans CR, Tiwari R, Nauta JJ, van der Waal I,
Snow GB. Recurrence at the primary site in head and neck cancer and
the significance of neck lymph node metastases as a prognostic
factor. Cancer 1994; 73: 187-90.
21. Hibbert J, Marks MJ, Winter PJ, Shaheen OH.
Prognostic factors in oral squamous cell carcinoma and their
relation to clinical staging. Clin Otolaryngol 1983; 8:
157-203.
|